<DOC>
	<DOCNO>NCT02663908</DOCNO>
	<brief_summary>The purpose trial test market drug advanced prostate cancer ( FIRMAGON ) reduce risk cardiovascular complication compare another market drug advanced prostate cancer ( LUPRON DEPOT ) patient prostate cancer cardiovascular disease .</brief_summary>
	<brief_title>A Trial Comparing Cardiovascular Safety Degarelix Versus Leuprolide Patients With Advanced Prostate Cancer Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Advanced prostate cancer Indication initiate androgen deprivation therapy ( ADT ) Predefined cardiovascular disease Previous current hormonal management prostate cancer ( unless terminate least 12 month prior trial ) Acute cardiovascular disease previous 30 day Patients candidate prostate cancer therapy curative intention ( e.g . prostatectomy , radiotherapy )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>